1 |
Jänne PA, Yang JCH, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J]. New England J Med, 2015, 372(18): 1689-1699.
|
2 |
张 剑,卢从华,李江华,等. 根据转录组学分析奥希替尼获得性耐药机制的研究[J/CD]. 中华肺部疾病杂志(电子版), 2024, 17(2): 195-200.
|
3 |
Stenmark H. Rab GTPases as coordinators of vesicle traffic[J]. Nat Rev Molecul Cell Biol, 2009, 10(8): 513-525.
|
4 |
Prashar A, Schnettger L, Bernard EM, et al. Rab GTPases in immunity and inflammation[J]. Front Cell Infect Microbiol, 2017, 7: 435.
|
5 |
Langemeyer L, Fröhlich F, Ungermann C. Rab GTPase function in endosome and lysosome biogenesis[J]. Trends Cell Biol, 2018, 28(11): 957-970.
|
6 |
Gong D, Liu X, Wu P, et al. Rab26 alleviates sepsis-induced immunosuppression as a master regulator of macrophage ferroptosis and polarization shift[J]. Free Rad Biol Med, 2024, 212: 271-283.
|
7 |
Li C, Fan Y, Lan TH, et al. Rab26 modulates the cell surface transport of α2-adrenergic receptors from the Golgi[J]. J Biolog Chem, 2012, 287(51): 42784-42794.
|
8 |
Dong W, He B, Qian H, et al. RAB26-dependent autophagy protects adherens junctional integrity in acute lung injury[J]. Autoph, 2018, 14(10): 1677-1692.
|
9 |
Tang ZH, Jiang XM, Guo X, et al. Characterization of Osimertinib(AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line[J]. Oncotarget,2016, 7(49): 81598-81610.
|
10 |
Ma CS, Lv QM, Zhang KR, et al. NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells[J]. Acta Pharmacol Sin, 2021, 42(4): 613-623.
|
11 |
Zalaquett Z, Catherine Rita Hachem M, Kassis Y, et al. Acquired resistance mechanisms to osimertinib: The constant battle[J]. Cancer Treatment Rev, 2023, 116: 102557.
|
12 |
Niederst MJ, Hu H, Mulvey HE, et al. The Allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies[J]. Clin Cancer Res, 2015, 21(17): 3924-3933.
|
13 |
Ou SHI, Agarwal N, Ali SM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression[J]. Lung Cancer (Amsterdam, Netherlands), 2016, 98: 59-61.
|
14 |
Ku BM, Choi MK, Sun JM, et al. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model[J]. PloS One, 2018, 13(4): e0194730.
|
15 |
Xiu W, Zhang Q, Yu M, et al. Case Report: outcome of osimertinib treatment in lung adenocarcinoma patients with acquired KRAS mutations[J]. Front Oncol, 2021, 11: 630256.
|
16 |
Díaz-Serrano A, Gella P, Jiménez E, et al. Targeting EGFR in lung cancer: Current standards and developments[J]. Drugs, 2018, 78(9): 893-911.
|
17 |
Liu K, Chen X, Wu L, et al. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition[J]. BMC Pulmon Med, 2021, 21(1): 163.
|
18 |
Weng CH, Chen LY, Lin YC, et al. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI[J]. Oncogene, 2019, 38(4): 455-468.
|
19 |
Jin H, Tang Y, Yang L, et al. Rab GTPases: Central coordinators of membrane trafficking in cancer[J]. Front Cell Development Biol, 2021, 9: 648384.
|
20 |
Liu J, Zheng X, Wu X. The Rab GTPase in the heart: Pivotal roles in development and disease[J]. Life Sci, 2022, 306: 120806.
|
21 |
Kiral FR, Kohrs FE, Jin EJ, et al. Rab GTPases and membrane trafficking in?neurodegeneration[J]. Current Biol: CB, 2018, 28(8): R471-R486.
|
22 |
Zhang X, Huang TY, Yancey J, et al. Role of rab GTPases in alzheimer’s disease[J]. ACS Chem Neurosci, 2019, 10(2): 828-838.
|
23 |
Liu N, Wu Z, Chen A, et al. SNRPB promotes the tumorigenic potential of NSCLC in part by regulating RAB26[J]. Cell Death Dis, 2019, 10(9): 667.
|
24 |
Ren H, Yang B, Li M, et al. RAB26 contributes to the progression of non-small cell lung cancer after being transcriptionally activated by SMAD3[J]. Bioengin, 2022, 13(4): 8064-8075.
|
25 |
Liu Q, Wang D, Xu Z, et al. Targeted delivery of rab26 siRNA with precisely tailored DNA prism for lung cancer therapy[J]. Chembiochem, 2019, 20(9): 1139-1144.
|
26 |
Zheng Y, Wu J, Chen H, et al. KLF4 targets RAB26 and decreases 5-FU resistance through inhibiting autophagy in colon cancer[J]. Cancer Biol Ther, 2023, 24(1): 2226353.
|
27 |
Liu H, Zhou Y, Qiu H, et al. Rab26 suppresses migration and invasion of breast cancer cells through mediating autophagic degradation of phosphorylated Src[J]. Cell Death Dis, 2021, 12(4): 284.
|
28 |
Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel?[J]. Nat Rev Cancer, 2014, 14(11): 709-721.
|
29 |
Chun KS, Kim DH, Surh YJ. Role of reductive versus oxidative stress in tumor progression and anticancer drug resistance[J]. Cells, 2021, 10(4): 758.
|
30 |
Zhang KR, Zhang YF, Lei HM, et al. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer[J]. Sci Translat Med, 2021, 13(614): eabg6428.
|
31 |
Meng Y, Lin W, Wang N, et al. Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3/SOCS3 and KEAP1/NRF2 pathways in non-small cell lung cancer[J]. Free Rad Biol Med, 2023, 196: 65-80.
|
32 |
Wu D, Wang Y, Hu J, et al. Rab26 promotes macrophage phagocytosis through regulation of MFN2 trafficking to mitochondria [J]. FEBS J. 2023, 290(16):4023-4039.
|
33 |
Hennig P, Fenini G, Di Filippo M, et al. The pathways underlying the multiple roles of p62 in inflammation and cancer[J]. Biomed, 2021, 9(7): 707.
|
34 |
Baird L, Yamamoto M. The molecular mechanisms regulating the KEAP1-NRF2 pathway[J]. Mol Cell Biol, 2020, 40(13): e00099-20.
|
35 |
Zhu L, He S, Huang L, et al. Chaperone-mediated autophagy degrades Keap1 and promotes Nrf2-mediated antioxidative response[J]. Aging Cell, 2022, 21(6): e13616.
|
36 |
Ni Y, Liu J, Zeng L, et al. Natural product manoalide promotes EGFR-TKI sensitivity of lung cancer cells by KRAS-ERK pathway and mitochondrial Ca2+ overload-induced ferroptosis[J]. Front Pharmacol, 2023, 13: 1109822.
|